When was Portal founded?

Portal was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is Portal located?

Portal is headquartered in Watertown, United States.

Who is the current CEO of Portal?

Armon Sharei of Portal. They have also founded 1 company.

How many employees does Portal have?

As of Jul 31, 2026, the latest employee count at Portal is 98.

Is Portal a funded company?

Portal is a funded company, having raised a total of $25.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 19, 2024.

When was the latest funding round of Portal?

Portal's latest funding was a $***** Seed round on May 15, 2026, with participation from 6 investors.

Where does Portal rank among its competitors?

Portal ranks 2nd amongst 82 active competitors, of which 31 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of Portal?

Portal's top competitors include Genedit, Genenta Science and SonoThera. Among them, SonoThera secured the most recent funding round in June, 2026.

Portal - 2026 Company Profile, Team, Funding & Competitors

Portal is a seed company based in Watertown (United States), founded in 2023 by Armon Sharei. It operates as a Provider of cell engineering and cell analytics across research and clinical applications. Portal has raised $25.7M in funding from investors like IA Ventures, NFX and Pear VC. The company has 82 active competitors, including 31 funded and 15 that have exited. Its top competitors include companies like Genedit, Genenta Science and SonoThera.

Company Details

Provider of cell engineering and cell analytics across research and clinical applications. The company's approach is for intracellular delivery, focused on accelerating advances enabled by the generation of RNA, gene editing, and molecular design technologies. The company's product suite is based on a proprietary mechanical delivery system capable of delivering many different types of cargo to a broad range of cell types.

Website: portal.bio
Email ID: *****@portal.bio

Key Metrics

Founded Year

2023

Location

Watertown, United States

Stage

Seed

Total Funding

$25.7M in 3 rounds

Latest Funding Round

Seed, May 15, 2026, $*****

Investors

IA Ventures & 8 more

Ranked

2^nd among 82 active competitors

Employee Count

98 as on Jul 31, 2026

Similar Companies

Genedit & 104 more

View Portal's full profile

Portal has raised a total funding of $25.7M over 3 rounds. Its first funding round was on Mar 19, 2024. Its latest funding round was a Seed round on May 15, 2026 for $*****. 6 investors participated in its latest round. Portal has 9 institutional investors.

Here is the list of recent funding rounds of Portal:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 15, 2026	1323778	Seed	9298066	9082958	1353331	5203797
Dec 11, 2024	2203702	Seed	7687872	9905655	3865683	Pear VC & 3 more
Mar 19, 2024	4340005	Seed	9200184	3421813	Pear VC	Conscience VC & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Portal's funding rounds and investors

The founders of Portal is Armon Sharei. Armon Sharei is the CEO of Portal.

Here are the details of Portal's key team members:

Armon Sharei: Founder & CEO of Portal.
Contact Info: 1 email address

View details of Portal's Founder profiles and Board Members

Portal's employee count trend

Portal has 98 employees as of Jul 26. Here is Portal's employee count trend over the years:

Uncover Portal's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Portal include Genedit, Genenta Science and SonoThera. Here is the list of Top 10 competitors of Portal, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, DCVC & 20 others	65/100
2nd	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	10X Capital, NFX & 7 others	61/100
3rd	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 3 others	58/100
4th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Arch Venture Partners, Vida Ventures & 21 others	57/100
5th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100
6th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Orbimed & 6 others	57/100
7th	ExpreS2ion Biotechnologies 2010, Copenhagen (Denmark), Public	Provider of recombinant protein production using an insect expression platform	-	Modelio Equity, Gemstone Capital & 2 others	52/100
8th	VIVEbiotech 2015, San Sebastian (Spain), Seed	Developer and manufacturer of lentiviral vectors	$3.86M	Inveready, Easo Ventures & 1 others	51/100
9th	Feldan 2007, Quebec City (Canada), Series B	Developing delivery system of proteins inside cells directly	$52.9M	Amgen, Genesys Capital & 12 others	50/100
10th	Vigene Biosciences 2012, Rockville (United States), Acquired	Developer of life science research reagents for drug discovery and functional genomics	$10.5M	Signet Healthcare Partners, CYwP Funds & 1 others	50/100